HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio
Summary
CHARLOTTESVILLE, Va., Feb. 10, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, has raised $40 million in a Series A financing. "We are excited to have attracted such an outstanding group of investors to support our progress in developing a new therapy for MMA and PA, two devastating diseases which currently have no pharmacological treatment options," said Jim Powers, Chairman and CEO of HemoShear. MMA and PA are diagnosed through newborn screening in the United States and select countries in Europe, the Middle East and the rest of the world. The diseases result in the buildup of toxic metabolites that can lead to frequent metabolic decompensations, severe organ damage, seizures, developmental deficits, and premature death. HemoShear Therapeutics, Inc. is a privately held clinical stage company developing treatments for rare metabolic disorders with significant unmet patient need.